Request Trial
limbeek_kerri-ann_5715
Kerri-Ann Limbeek, partner at Desmarais and trial lead for Ravgen.
25 January 2024FeaturesPharmaSarah Speight
|

Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera

Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026   In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.
Pharma
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
15 October 2026   A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.
Pharma
Accord’s generic hopes dashed in cyanide antidote ruling
14 October 2026   Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.


Editor's picks

Boston Scientific expands dispute with J&J unit over cardiac-access technology
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026

Editor's picks

MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
Haynes Boone expands in California with new office
Accord’s generic hopes dashed in cyanide antidote ruling
Novo’s semaglutide protection weakens after European ruling
Boston Scientific expands dispute with J&J unit over cardiac-access technology